NEW YORK (GenomeWeb News) – Genomic Health said after the close of the market on Monday that it is exclusively licensing Almac Group's technology and intellectual property to develop a multi-gene test for the prediction of benefits from DNA damage-based chemotherapy drugs.

Genomic Health will also validate and validate the test, which is focused on drugs such as the commonly used anthracycline-based regimens. The company said such a test would be especially useful for high-risk breast cancer patients who are eligible for chemotherapy based on their Oncotype DX score.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.

May
15
Sponsored by
Tecan

This webinar will discuss how an algorithm-driven synthetic biology system can enable engineering of biological systems for a range of applications.

Jun
20
Sponsored by
PerkinElmer

In this webinar, Michael Quail of the R&D Sequencing team at the Wellcome Trust Sanger Institute will provide an expert perspective on library prep for next-generation sequencing.

Jun
28
Sponsored by
PerkinElmer

This webinar will review a standardized, high-throughput, and fully automated library prep protocol for human metagenomic analysis.